Abstract
Pharmaceutical companies are major sponsors of biomedical research. Most scholars and policymakers focus their attention on government and academic oversight activities, however. In this article, I consider the role of pharmaceutical companies’ internal ethics statements in guiding decisions about corporate research and development (R&D). I review materials from drug company websites and contributions from the business and medical ethics literature that address ethical responsibilities of businesses in general and pharmaceutical companies in particular. I discuss positive and negative uses of pharmaceutical companies’ ethics materials and describe shortcomings in the companies’ existing ethics programs. To guide employees and reassure outsiders, companies must add rigor, independence, and transparency to their R&D ethics programs.
Article PDF
Similar content being viewed by others
References
Amgen. Available at http://www.amgen.com.
M. Angell (2004) The Truth about the Drug Companies: How They Deceive Us, and What to Do about It Random House New York
AstraZeneca. Available at http://www.astrazeneca.com.
J. Avorn (2004) Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs Knopf New York
Berenson, A. “Despite Vow, Drug Makers Still Withhold Data.” New York Times. May 31, 2005, A1.
D. Brock (2001) ArticleTitleSome Questions about the Moral Responsibilities of Drug Companies in Developing Companies Developing World Bioethics 1 33–37 Occurrence Handle10.1111/1471-8847.00005
J. Couzin (2005) ArticleTitleFacing Criticism, Industry Offers to Share Data Science 307 89 Occurrence Handle10.1126/science.1102004
T. Croghan P. Pittman (2004) ArticleTitleThe Medicine Cabinet: What’s in It, Why, and Can We Change the Contents? A Framework for Aligning Business Objectives with Medical Need Health Affairs 23 23–33 Occurrence Handle10.1377/hlthaff.23.1.23
C. Angelis ParticleDe J. Drazen F. Frizelle et al. (2004) ArticleTitleClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors New England Journal of Medicine 351 1250–1251 Occurrence Handle10.1056/NEJMe048225
J. Maistre Particlede (1992)) “Letter to X” J. Kaplan (Eds) Bartlett’s Familiar Quotations EditionNumber16 Little, Brown Boston
R. Dhanda (2002) Guiding Icarus: Merging Bioethics with Corporate Interests John Wiley & Sons New York
R. Dresser (2001) When Science Offers Salvation: Patient Advocacy and Research Ethics Oxford University Press New York
R. Dresser (2005) ArticleTitleA New Era in Drug Regulation? Hastings Center Report 35 IssueID3 10–11 Occurrence Handle10.1353/hcr.2005.0060
G. DuVal (2004) ArticleTitleInstitutional Conflicts of Interest: Protecting Human Subjects, Scientific Integrity, and Institutional Accountability Journal of Law, Medicine & Ethics 32 613–625
M. Eaton (2004) Ethics and the Business of Bioscience Stanford Business Books Palo Alto
Friedman, M. “The Social Responsibility of Business Is to Increase Its Profits.” New York Times Magazine, September 13, 1970, 32–33, 122–126.
GlaxoSmithKline. Available at http://www.gsk.com.
Goodpasture, K. and J. Mathews. “Can a Corporation Have a Conscience?” In Harvard Business Review on Corporate Responsibility. 131–155. Boston: Harvard Business School Press, 2003.
Hahn, H. “The Flaws in a Heart Device.” New York Times, May 31, 2005, A18.
Johnson & Johnson. Available at http://www.jnj.com.
N. Levinsky (2002) ArticleTitleNonfinancial Conflicts of Interest in Research New England Journal of Medicine 347 759–761 Occurrence Handle10.1056/NEJMsb020853
M. Mello B. Clarridge D. Studdert (2005) ArticleTitleAcademic Medical Centers’ Standards for Clinical-Trial Agreements with Industry New England Journal of Medicine 352 2202–2210 Occurrence Handle10.1056/NEJMsa044115
Merck. Available at http://www.merck.com.
NDCHealth, “Excerpts from 2005 Pharma Insight.” Available at http://www.ndchealth.com/press_center/uspharmaindustrydata.asp.
Nielson, N. “Pfizer: A New Mission in Action.” Available at http://www.pfizer.com/subsites/corporate_citizenship/how_were_changing.html.
N. Olsen (2005) ArticleTitleTailoring Arthritis Therapy in the Wake of the NSAID Crisis New England Journal of Medicine 352 2578–2580 Occurrence Handle10.1056/NEJMp058105
L.S. Paine (2003) Value Shift: Why Companies Must Merge Social and Financial Imperatives to Achieve Superior Performance McGraw-Hill New York
Pfizer, Inc. Available at http://www.pfizer.com.
PhRMA. Available at http://www.phrma.org.
Porter, M. and Kramer, M. “The Competitive Advantage of Corporate Philanthropy.” In Harvard Business Review on Corporate Responsibility. 27–64. Boston: Harvard Business School Press, 2003.
B. Psaty C. Furberg W. Ray N. Weiss (2004) ArticleTitlePotential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis Journal of the American Medical Association 292 2629
Relman, A. and M. Angell, “America’s Other Drug Problem.” The New Republic, December 16, 2002, 27–41.
Roche Group. Available at http://www.roche.com.
E. Spencer A. Mills M. Rorty P. Werhane (2000) Organizational Ethics in Health Care Oxford University Press New York
R. Steinbrook (2005) ArticleTitleGag Clauses in Clinical-Trial Agreements New England Journal of Medicine 352 2160–2162 Occurrence Handle10.1056/NEJMp048353
B. Strom (2004) ArticleTitlePotential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint Journal of the American Medical Association 292 2643–2646 Occurrence Handle10.1001/jama.292.21.2643
Thompson, D. “The Privatization of Business Ethics.” In Restoring Responsibility: Ethics in Government, Business, and Healthcare. Cambridge: Cambridge University Press, 2005.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dresser, R. Private-Sector Research Ethics: Marketing or Good Conflicts Management? The 2005 John J. Conley Lecture on Medical Ethics. Theor Med Bioeth 27, 115–139 (2006). https://doi.org/10.1007/s11017-005-5289-5
Issue Date:
DOI: https://doi.org/10.1007/s11017-005-5289-5